Incyte Corporation is going to have a second go at getting its PD1 inhibitor Zynyz (retifanlimab) approved as the first anti PD-1/PD-L1 inhibitor for squamous cell anal carcinoma (SCAC) following a hit in the Phase III POD1UM-303/InterAACT 2 trial presented at the European Society for Medical Oncology meeting in Barcelona, Spain, on 14 September.
ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM
Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.
More from ESMO
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.